



COPY OF PAPERS  
ORIGINALLY FILED

1636

Attorney Docket No. 5470.148CX2

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Baldwin, et al.  
Serial No.: 08/959,160  
Filed: October 28, 1997  
For: **USE OF NF-κB INHIBITION IN COMBINATION THERAPY  
FOR CANCER**

Group Art Unit: 1636

# 33/D  
Teta  
3/12/03

February 13, 2003

Commissioner for Patents  
Washington, DC 20231

**RESPONSE TO OFFICIAL ACTION**

**In the claims:**

Please cancel claims 4 and 9-10, without prejudice or disclaimer

**Remarks**

Dear Sir:


In response to the Official Action dated January 13, 2003, Applicant hereby

**RECEIVED** selects the species doxorubicin. All pending claims are currently readable thereon.

Claims 4 and 9-10 have been cancelled above, consistent with the helpful  
suggestions provided by the Examiner on page 4 of the Official Action.

MAR 04 2003  
TECH CENTER 1600/2900

Respectfully submitted,

  
Kenneth D. Sibley  
Registration No. 31,665




20792

PATENT TRADEMARK OFFICE

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on February 13, 2003.



Vickie Diane Prior

Date of Signature: February 13, 2003

Doc. No. 292926